Creative Biolabs Advances In Vitro Modeling with 3D Organoids and Tissue Slice Models
TL;DR
Creative Biolabs' 3D organoid models offer a competitive edge in precision medicine by enabling targeted drug testing and disease modeling with patient-specific genetic backgrounds.
Creative Biolabs utilizes stem cells or tumor tissues to create 3D organoid models, providing a detailed approach for research on organ development and drug sensitivity.
The advancement of 3D organoid models by Creative Biolabs contributes to a better future by enhancing precision medicine and reducing reliance on animal testing.
Discover how Creative Biolabs is revolutionizing research with 3D organoid models that mimic human organs for groundbreaking disease and drug studies.
Found this article helpful?
Share it with your network and spread the knowledge!
Creative Biolabs is pioneering a dual-model approach in in vitro modeling by integrating 3D organoids and precision-cut tissue slices (PCTS), marking a significant advancement in precision medicine research. This innovative strategy addresses the limitations of traditional models by offering more physiologically relevant and translatable data, crucial for drug development and disease modeling.
The 3D organoid models, derived from stem cells or tumor tissues, replicate the three-dimensional architecture and functions of human organs, making them invaluable for studying organ development, disease mechanisms, and drug responses. Creative Biolabs offers a variety of organoid models, including 3D Tumor Organoid Models for drug sensitivity assessment and Customized 3D Organoid Models tailored to specific research needs using client-provided cells or induced pluripotent stem cells (iPSCs).
However, recognizing that organoids alone cannot address all research challenges, Creative Biolabs also employs PCTS models. These models are essential for investigating short-term effects and drug distribution within organs, providing an ex vivo platform that closely mimics in vivo conditions. The company's PCTS models cover critical organs like the heart and lung, available from both healthy and diseased tissues to suit diverse project requirements.
By combining these two approaches, Creative Biolabs enables a comprehensive research framework. Early drug screening can be efficiently conducted using PCTS models to evaluate efficacy and toxicity, followed by in-depth mechanistic studies with organoids. This synergistic method not only accelerates the drug discovery process but also enhances the reliability of translating experimental findings into clinical applications.
As the biopharmaceutical industry increasingly adopts human-relevant models, Creative Biolabs' 3D biology platform stands out as a vital resource for global research institutions and companies. The integration of organoid and PCTS systems exemplifies the company's commitment to advancing precision medicine, from model development to the practical application of research outcomes. For further details on their 3D biological modeling services, visit https://www.creative-biolabs.com/3d-biology/.
Curated from 24-7 Press Release
